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FDA and CDC Issue Alert on Menactra Meningococcal Vaccine and Guillain 
Barre Syndrome
The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) are alerting 
consumers and health care providers to five reports of Guillain Barre Syndrome (GBS) following administration of 
Meningococcal Conjugate Vaccine A, C, Y, and W135 (trade name Menactra), manufactured by Sanofi Pasteur. It 
is not known yet whether these cases were caused by the vaccine or are coincidental. FDA and CDC are sharing 
this information with the public now and actively investigating the situation because of its potentially serious 
nature.
Guillain Barre Syndrome (GBS) is a serious neurological disorder that can occur, often in healthy individuals, 
either spontaneously or after certain infections. G BS  typically causes increasing weakness in the legs and arms 
that can be severe and require hospitalization.
Meningococcal infection, which Menactra prevents, is a major cause of bacterial meningitis, affecting 
approximately 1 in 100,000 people annually. The infection can be life threatening:
10-14 percent of cases are fatal and 11-19 percent of survivors may have permanent disability.
According to Jesse Goodman, MD, Director of FDA's Center for Biologics Evaluation and Research, at the 
present time there are no changes in recommendations for vaccination; individuals should continue to follow their 
doctors' recommendations. FDA and CDC are not able to determine if any or all of the cases were due to 
vaccination. The current information is very preliminary and the two agencies are continuing to evaluate the 
situation.
Because of the potentially serious nature of this matter, FDA and CDC are asking any persons with knowledge of 
any possible cases of GBS occurring after Menactra to report them to the Vaccine Adverse Event Reporting 
System (VAERS) to help the agencies further evaluate the matter. Individuals can report to VAERS on the web at 
www.vaers.hhs.gov or by phone at 1-800-822-7967.
The five cases of G BS reported following administration of Menactra occurred in individuals living in NY, OH, PA, 
and NJ. All five patients were 17 or 18 years of age and developed weakness or abnormal sensations in the arms 
or legs, two-four weeks after vaccination. All individuals are reported to be recovering or to have recovered. More 
than 2.5 million doses of Menactra vaccine have been distributed to date. The rate of G BS based on the number 
of cases reported following administration of Menactra is similar to what might have been expected to occur by 
coincidence, that is, even without vaccination. However, the timing of the events is of concern. Also, vaccine 
adverse events are not always reported to FDA so there may be additional cases of which we are unaware at this 
time.
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Prelicensure studies conducted by Sanofi Pasteur of more than 7000 recipients of Menactra showed no G BS 
cases. CDC conducted a rapid study using available health care organization databases and found that no cases 
of G BS have been reported to date among 110,000 Menactra recipients.
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national and international
organizations.
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